Kadmon Holdings Inc

Kadmon — Technical Presentation (May 2020)

23 slides from Kadmon's technical presentation, May 21, 2020

  1. Slide 1: ROCKstar: Pivotal Trial of Belumosudil (KD025) in cGVHD

    8 Kadmon ROCkKstar: Pivotal Trial of Belumosudil (KDO25) in CGVHD KD025-213 Primary Analysis Topline Results May 21°¢, 2020

  2. Slide 2: Forward-Looking Statement

    Forward-Looking Statement This presentation contains “forward-looking” statements that are based on the beliefs and assumptions of, and on information currently available to, management of Kadmon Holdings, Inc. (the “Company’). All statements other than statements of historical fact contained in thi

  3. Slide 3: CEO Opening Remarks

    CEO Opening Remarks Harlan W. Waksal, M.D., President and CEO

  4. Slide 4: ROCKstar (KD025-213): Primary Analysis Outcomes

    ROCKstar (KD025-213): Primary Analysis Outcomes e Belumosudil (KD025) met the primary endpoint of Overall Response Rate (ORR) in the pivotal trial in cGVHD patients who have received 2 or more prior lines of systemic therapy: — 73% ORR with KD025 200 mg QD (95% Cl: 60%, 83%) — 74% ORR with KD025 200

  5. Slide 5: ROCKstar Primary Analysis Results

    ROCKstar Primary Analysis Results KD025-213: Pivotal Clinical Trial of Belumosudil (KD025) in c6VHD Sanjay Aggarwal, M.D., Senior Vice President, Clinical Development

  6. Slide 6: ROCKstar: Pivotal Trial of Belumosudil (KD025) in cGVHD

    ROCKstar: Pivotal Trial of Belumosudil (KD025) in cGVHD ROCKstar (KD025-213): A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy Primary Endpoint: + ORR, per 2014 NIH criteria KD025

  7. Slide 7: ROCKstar: Statistical Analysis Plan

    ROCkKstar: Statistical Analysis Plan Primary Endpoint: ORR Statistical significance is achieved if the lower bound of the 95% Cl of ORR exceeds 30% a Primary endpoint met at interim analysis pet 2 months after completion of enrollment y Data presented at TCT, February 2020 macy 6 months after comple

  8. Slide 8: ROCKstar: Advanced Patient Population

    ROCkKstar: Advanced Patient Population Demographics and Baseline Characteristics Demographics KD025 QD (n=66) KD025 BID (n=66) Median age [years (range)] 53 (21-77) 57 (21-77) Male (%) 64 50 Median prior lines of therapy 2 4 Median time from cGVHD diagnosis to enrollment (months) 25 30 NIH Severe cG

  9. Slide 9: ROCKstar Met Primary Endpoint

    ROCKstar Met Primary Endpoint 100% 95% 73% 74% e Belumosudil (KD025) achieved 90% (95% Cl: 60%, 83%)" (95% Cl: 62%, 84%)? clinically and statistically significant ene ORRs in both arms fo 75% ; 70% e Complete responses have observed in 65% all affected organ systems 60% 55% e Four patients have achi

  10. Slide 10: ROCKstar Met Primary Endpoint

    ROCKstar Met Primary Endpoint 100% 95% 73% 74% e Belumosudil (KD025) achieved 90% (95% Cl: 60%, 83%)" (95% Cl: 62%, 84%)? clinically and statistically significant 85% ORRs in both arms 80% 75% 70% 65% 60% 55% 50% 45% 40% 35% 30% me 25% 20% 15% 10% 5% 0% e Complete responses have observed in all affe

  11. Slide 11: ROCKstar: Responses Observed Across All Key Subgroups

    ROCkKstar: Responses Observed Across All Key Subgroups mITT —_o— 200 mg QD (n=66, 73%) —o— 200 mg BID (n=66, 74%) Prior Lines of Therapy Oe = 4 (n=65, 71%) —e— <4 (1-67, 76%) NIH Severity Best Response to Prior Line on co Severe (n=89, 72%) a Refractory (n=79, 73%) —_——e——. Non-Severe (n=43, 77%) ——

  12. Slide 12: ROCKstar: Durability of Response

    ROCkKstar: Durability of Response e Durable responses achieved with belumosudil (KD025): — 49% of responders have maintained responses for = 20 weeks — Median duration of response (DOR) has not yet been reached — ROCKstar durability data continue to mature e In earlier Phase 2a trial of belumosudil

  13. Slide 13: ROCKstar: Safety and Tolerability

    ROCkKstar: Safety and Tolerability KD025@D KD025 BID e AEs were overall consistent with those expected in Commons epee dee m8) (n=66) (n=66) cGVHD patients receiving corticosteroids and other immunosuppressants All Grade, in 220% ¢ No CMV infection or reactivation observed Fatigue 26 (39) 16 (24) e

  14. Slide 14: ROCKstar Pivotal Trial: Primary Analysis Summary

    ROCkKstar Pivotal Trial: Primary Analysis Summary e Belumosudil (KD025) met the primary endpoint in pivotal trial in cGVHD: — 73% and 74% ORR with belumosudil 200 mg QD and 200 mg BID, respectively ¢ 49% of responders have maintained responses for 220 weeks — Median DOR has not yet been reached; dur

  15. Slide 15: Commercial Overview

    Commercial Overview Haya Taitel, RPh, Senior Vice President, Chief Commercial Officer

  16. Slide 16: Significant cGVHD Market with Unmet Medical Needs

    Significant CGVHD Market with Unmet Medical Needs 7,000 — 10,000 cGVHD patients require additional systemic therapy beyond steroids e Significant cGVHD market — 5,000 new cGVHD patients/year’ — 5-year overall survival of 55%? e Unmet therapeutic needs — Steroids are standard of care in frontline tre

  17. Slide 17: Patients are Concentrated at Academic Transplant Centers

    Patients are Concentrated at Academic Transplant Centers 80% of cGVHD Patients are Treated at 70 Transplant Centers a : | A Efficient Field a . - Dees ¢ . Footprint <15 total field associates to address cGVHD market Top Allo-HCT center by volume @ KD025-213 trial site Dark green indicates higher all

  18. Slide 18: Commercial Infrastructure in Place

    Commercial Infrastructure in Place Supply Chain i Legal / Compliance Regulatory Affairs Quality Assurance Kadmon Pharmaceuticals: Commercial operation based in Warrendale, PA

  19. Slide 19: Components in Place to Launch and Commercialize KD025

    Components in Place to Launch and Commercialize KD025 Existing Commercial Infrastructure Experienced Team Strategic Launch Plan

  20. Slide 20: Belumosudil in cGVHD: Path Forward

    Belumosudil in cGVHD: Path Forward Harlan W. Waksal, M.D., President and CEO $ Kadmon:

  21. Slide 21: Belumosudil: A Novel cGVHD Treatment

    Belumosudil: A Novel cGVHD Treatment Observed in KD025-208 and ROCKstar (KD025-213) Clinical Trials VY Efficacy — high response rates in advanced cGVHD patients Os Improvement in QOL * KD025-208 follow-up data 8 kadmon

  22. Slide 22: Belumosudil (KD025) in cGVHD: Path Forward

    Belumosudil (KDO25) in cGVHD: Path Forward * NDA submission for belumosudil (KD025) in cGVHD planned Q4 2020 — Pre-NDA meeting with FDA took place in March 2020 — Belumosudil is being reviewed under Real-Time Oncology Review (RTOR) Pilot Program — FDA Breakthrough Therapy Designation and Orphan Drug

  23. Slide 23: Q&A

    Q&A

Kadmon Holdings — Technical Presentation (May 2020) on 6ix